Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Sareum Holdings ( (GB:SAR) ) has issued an update.
Sareum Holdings announced that all resolutions were passed during its Annual General Meeting, reflecting shareholder confidence in the company’s strategic direction. This outcome is significant for Sareum as it continues developing its promising kinase inhibitors, which have completed Phase 1 trials, potentially strengthening its position in the biotechnology market.
More about Sareum Holdings
Sareum Holdings is a clinical-stage biotechnology company based in Cambridge, UK, focusing on the development of next-generation kinase inhibitors for autoimmune diseases and cancer. Their lead candidates include SDC-1801, targeting autoimmune diseases such as psoriasis, and SDC-1802, which is aimed at cancer immunotherapy. The company is listed on the AIM market of the London Stock Exchange under the ticker SAR.
YTD Price Performance: -53.78%
Average Trading Volume: 385,721
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £34.31M
Find detailed analytics on SAR stock on TipRanks’ Stock Analysis page.
